Roivant Sciences Ltd at Jefferies Healthcare Conference Transcript
Good morning. Welcome, everybody, to the 2023 Jefferies Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. And I have the great pleasure of having Roivant here with us for a fireside, and we have CEO Matt Gline here.
Questions & Answers
Matt, I mean, there's obviously been a ton of interest around the company, around the pipeline. You guys had some really interesting and promising data, particularly around TL1A, which is only one aspect of the story.
So maybe, before we start off, just level-set us. Talk about some of the Phase 2 data you guys had in January, the induction data in ulcerative colitis, and the path forward and some of the next steps for that program.
Yeah. Perfect. Thank you. Thank you, Dennis. Thanks for having us. We're obviously really happy to be here. It's nice to have a conference so close to home; our office is just across the street.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
